Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine

Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine

The vaccination campaign against SARS-CoV-2 relies on the world-wide availability of effective vaccines, with a potential need of 20 billion vaccine doses to fully vaccinate the world population. To reach this goal, the manufacturing and logistic processes should be affordable to all countries, irre...

Full description

Bibliographic Details
Main Authors: Alberto Grandi, Michele Tomasi, Irfan Ullah, Cinzia Bertelli, Teresa Vanzo, Silvia Accordini, Assunta Gagliardi, Ilaria Zanella, Mattia Benedet, Riccardo Corbellari, Gabriele Di Lascio, Silvia Tamburini, Elena Caproni, Lorenzo Croia, Micol Ravà, Valeria Fumagalli, Pietro Di Lucia, Davide Marotta, Eleonora Sala, Matteo Iannacone, Priti Kumar, Walther Mothes, Pradeep D. Uchil, Peter Cherepanov, Martino Bolognesi, Massimo Pizzato, Guido Grandi
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Vaccines
Subjects:
SARS-CoV-2
OMV-based vaccine
RBD neutralizing epitopes
OMV engineering
cross-protective vaccine
Online Access:https://www.mdpi.com/2076-393X/11/10/1546

Internet

https://www.mdpi.com/2076-393X/11/10/1546

Similar Items